Summary:
This phase IIIb trial investigates the combination of Vesicare (Solifenacin)Plus Myrbetriq (Mirabegron) compared to Vesicare (Solifenacin) alone. Each of the study drugs works in a different way to each other, so the investigational combination is being evaluated to see if it may offer the additional relief for patient suffering from the symptoms of overactive bladder.
Qualified Participants Must:
• Be at least 18 years of age
•
Have symptoms of OAB (urinary frequency and urgency with urgency incontinence) for at least 3 months prior to screen visit
•
Have symptoms of “wet” OAB (urinary frequency and urgency with incontinence or mixed incontinence), and reports an average of at least 2 incontinence episodes per 24 period
Qualified Participants May Receive:
Study-related care, monitoring, study drug and compensation up to $500 for their time and travel expense.